CD274 and cancer: Immunotherapy is gaining momentum as a promising therapeutic approach for cancer, in which, immune cells are able to identify and eliminate cancer cells by initiating the cancer‐immune cycle.[1] Especially, immune checkpoint blockade (ICB) therapy targeting PD1/PDL1 axis has demonstrated excellent clinical benefits as the standard of care for numerous cancers.